Anti-TNF-α drugs, such as Infliximab, act as a mild anti-inflammatory and have a well-demonstrated ability to reduce levels of the cytokines associated with poor COVID-19 prognosis [61,62]. This evidence concerns the gene TNF and COVID-19.